Context Therapeutics (NASDAQ:CNTX - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.
Several other analysts have also weighed in on CNTX. Guggenheim began coverage on shares of Context Therapeutics in a report on Thursday, September 18th. They set a "buy" rating and a $5.00 price objective for the company. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, August 7th. HC Wainwright dropped their price objective on shares of Context Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Piper Sandler reissued an "overweight" rating and issued a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. Finally, Cantor Fitzgerald initiated coverage on shares of Context Therapeutics in a report on Thursday, October 2nd. They issued an "overweight" rating for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $5.20.
Check Out Our Latest Research Report on Context Therapeutics
Context Therapeutics Stock Up 0.9%
CNTX traded up $0.01 during midday trading on Wednesday, reaching $1.14. 236,892 shares of the company's stock were exchanged, compared to its average volume of 263,126. The firm has a market capitalization of $102.26 million, a price-to-earnings ratio of -3.17 and a beta of 1.93. Context Therapeutics has a one year low of $0.49 and a one year high of $2.59. The business has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $0.77.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). As a group, research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.
Hedge Funds Weigh In On Context Therapeutics
An institutional investor recently raised its position in Context Therapeutics stock. Millennium Management LLC lifted its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 24.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 178,718 shares of the company's stock after purchasing an additional 34,835 shares during the quarter. Millennium Management LLC owned 0.24% of Context Therapeutics worth $188,000 at the end of the most recent reporting period. 14.03% of the stock is owned by institutional investors.
Context Therapeutics Company Profile
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
